These results suggest that A20 may function as an enhancer in the tumor biology of CCA, which is consistent with previous studies of other malignant solid tumors, such as undifferentiated nasopharyngeal carcinoma, poorly differentiated head and neck squamous cell carcinoma [25], glioma [26, 27], glioblastoma [28], inflammatory breast cancer [29], and hepatocellular carcinoma [30], where A20 expression was related to an undesirable prognosis. This evidence concerns the gene TNFAIP3 and hepatocellular carcinoma.